MUC16 and ovarian cancer: In their study, a single infusion of ipilimumab (3 mg/kg) in two stage IV ovarian cancer patients previously vaccinated with granulocyte-macrophage colony-stimulating factor modified irradiated autologous tumor cells (GVAX) was well tolerated, and decreased or stabilized the CA-125 (cancer antigen 125) levels of several months’ duration.